Auxo Firm Directory · Independent Research Profile

Abry Partners

Abry Partners is a Boston-based, sector-focused private equity investment firm founded in 1989. It invests throughout North America and Europe and states that it targets middle-market companies with investment sizes from $20 million to $200 million.

Key takeaway

What stands out about Abry Partners

Abry Partners publicly describes a multi-strategy investment platform spanning controlling private equity, preferred-stock minority investments and first- and second-lien bank debt securities. Its stated focus is profitable middle-market companies in communications, media, information, business services and related sectors, with target investment sizes from $20 million to $200 million.[1][2][3][5][8]

What does Abry Partners invest in?

Abry Partners is a Boston-based, sector-focused private equity investment firm founded in 1989. The firm states that it invests throughout North America and Europe and targets middle-market companies.

Abry publicly describes investments in private equity, preferred stock and debt securities, with the ability to invest across the capital structure.[1][2][3]

Abry describes four fund strategies: controlling private equity, controlling heritage private equity, preferred-stock minority investments and first- and second-lien bank debt securities.

Its flagship and heritage funds typically make controlling investments. Its senior-equity fund typically makes preferred-stock minority investments, while its senior-debt fund invests in first- and second-lien bank debt securities.[2]

Owners evaluating a financial buyer can compare the offer with independent valuation analysis, understand how acquirers approach transactions through Auxo’s buy-side M&A process guide, and consider whether a full or partial sale best fits their objectives.

Published size criteriaPublicly stated range
Lower published point$20MILLION
Upper published point$200MILLION

Published criteria: Abry targets middle-market companies and stated investment sizes from $20 million to $200 million. It also identifies profitability, recurring revenues, high barriers to competitive entry, operating leverage, high free cash flow and multiple value-creation opportunities as target characteristics.[2][3]

What should a business owner evaluate before considering a transaction with Abry Partners?

An owner evaluating Abry can clarify which ownership or control position the firm would seek and which fund strategy would provide the capital. The available structures include controlling private equity, preferred-stock minority investment and first- or second-lien debt securities.

Other points to clarify include how the $20 million to $200 million target investment size would apply to the opportunity, the proposed governance and rollover-equity arrangements, management incentives, follow-on capital, investment horizon, exit approach, assigned operating professionals, add-on acquisition and international expansion plans, financing assumptions, transaction costs, exclusivity terms and diligence requirements.[2][3][4]

01

What ownership or control position would Abry seek for this business, and which fund strategy would provide the capital

Abry publicly describes controlling private equity, preferred-stock minority and debt strategies, while its 2026 portfolio update identifies majority, minority and structured-equity opportunities.[2][4]
02

How does Abry define the $20 million to $200 million target investment size for this opportunity

Abry states that it targets investment sizes from $20 million to $200 million in middle-market companies.[3]
03

What governance, rollover-equity, management-incentive and follow-on-capital terms are typical

The public criteria and structure disclosures establish the investment context, but do not specify these transaction terms.[2][3]

What companies does Abry Partners target?

Abry states that it targets profitable companies with recurring revenues, high barriers to competitive entry, operating leverage, high free cash flow and multiple opportunities for value creation. The firm targets middle-market companies and stated investment sizes from $20 million to $200 million.[3]

Abry’s stated areas of expertise include business and facility services; communications; data centers and managed IT services; government services; healthcare IT and services; human capital management; insurance and financial services; outsourced professional services; and media and entertainment.[3]

Abry states that its team invests throughout North America and Europe. Its 2026 portfolio update also describes majority, minority and structured-equity opportunities across those regions.[1][4]

Abry’s public materials show activity across controlling, minority and structured-equity opportunities. Its 2026 portfolio update states that the firm continued to target majority, minority and structured-equity investments across North America and Europe.

Public transaction materials also identify add-on activity during Abry’s ownership of Centauri Health Solutions: Centauri acquired Secure Exchange Solutions in 2021 and MedAllies in 2025.[4][7]

Publicly identified investment activity includes Confirma Software, Edenred Pay North America, Centauri Health Solutions, Prime Capital Financial and European Dynamics. The examples reflect multiple transaction structures, including a strategic minority investment in European Dynamics, a convertible preferred-stock investment in Edenred Pay North America and a continuation vehicle for Centauri Health Solutions.[5][6][7][8][9]

On September 24, 2026, Abry announced a definitive agreement to sell Confirma Software to Main Capital Partners after a seven-year partnership. The announcement states that Confirma had completed 29 acquisitions and grown to more than €104 million of revenue and more than 25,000 customers.

On July 31, 2026, Abry announced a strategic partnership and investment in Edenred Pay North America involving an initial US$75 million cash investment and convertible preferred shares potentially convertible into 40% of common shares on a fully diluted basis.

On June 15, 2026, Abry announced the closing of a $780 million continuation vehicle for Centauri Health Solutions. On August 7, 2026, it announced the exit of its investment in Prime Capital Financial, with Carlyle agreeing to acquire a minority ownership interest. On April 10, 2025, Abry joined CAPZA in a strategic minority investment in European Dynamics through its Senior Equity Fund.[5][6][7][8][9]

What is not clear from Abry Partners's public investment criteria?

Financial terms of the Confirma Software sale were not disclosed. Financial terms of the Prime Capital Financial exit transaction were likewise not disclosed.

Abry’s About page does not state a universal expected ownership duration, investment horizon or exit timetable for Abry’s investments. Individual transactions may provide transaction-specific duration information, such as the seven-year Confirma partnership.[3][5][8]

Questions to ask when evaluating Abry Partners as a buyer or investment partner

What ownership or control position would Abry seek for this business, and which fund strategy would provide the capital?
Abry publicly describes controlling private equity, preferred-stock minority and debt strategies, while its 2026 portfolio update identifies majority, minority and structured-equity opportunities.[2][4]
How does Abry define the $20 million to $200 million target investment size for this opportunity?
Abry states that it targets investment sizes from $20 million to $200 million in middle-market companies.[3]
What governance, rollover-equity, management-incentive and follow-on-capital terms are typical?
The public criteria and structure disclosures establish the investment context, but do not specify these transaction terms.[2][3]
What is the expected investment horizon or exit approach for this specific transaction?
Abry’s About page does not state a universal expected ownership duration, investment horizon or exit timetable.[3]
Which operating professionals and sector resources would be assigned?
Abry identifies multiple sector areas of expertise and publicly describes investment activity across those sectors.[3]
How does Abry evaluate add-on acquisitions, international expansion, and organic versus inorganic growth?
Abry’s public transaction examples include Centauri Health Solutions’ acquisitions of Secure Exchange Solutions in 2021 and MedAllies in 2025. A separate Confirma announcement states that Confirma had completed 29 acquisitions and that the parties had a seven-year partnership.[5][7]
What transaction costs, financing assumptions, exclusivity terms and diligence requirements would apply?
Abry publicly describes investments across the capital structure, including private equity, preferred stock and debt securities. The terms for this opportunity should be clarified.[2]

Sources & research notes

Public-source research
  1. Official website / firm overview
  2. Services / capabilities
  3. Investment strategy
  4. Transaction / portfolio evidence
  5. Transaction / portfolio evidence
  6. Transaction / portfolio evidence
  7. Transaction / portfolio evidence
  8. Transaction / portfolio evidence
  9. Transaction / portfolio evidence
Prepared and reviewed by: Auxo Capital AdvisorsEvidence standard: Public-source verification

How this profile was researched

Auxo profiles are prepared from publicly available primary and authoritative sources and reviewed for entity identity, factual support and disclosure consistency. When a fact cannot be supported by the reviewed public record, the profile identifies it as something to confirm directly rather than inferring it.

Independent profile & regulatory context

Independent research profile

This profile was prepared by Auxo Capital Advisors from publicly available information believed to be reliable and is provided solely for informational and educational purposes. It is not an endorsement, recommendation, ranking, solicitation, or representation regarding the profiled firm, its services, qualifications, transaction experience, regulatory status, financial condition, or suitability for any particular person, company, transaction, or investment.

Information obtained from third-party and public sources may be incomplete, inaccurate, outdated, or subject to change, and Auxo Capital Advisors makes no representation or warranty, express or implied, as to its accuracy, completeness, or timeliness. Readers should conduct their own independent diligence and consult appropriate professional advisers before engaging any advisor, intermediary, investor, lender, acquirer, or other transaction counterparty.

Broker-dealer and securities disclosure

Auxo Capital Advisors is an affiliate of Weild & Co., Member FINRA | SIPC. Securities-related activities and securities transactions are conducted through Weild & Co.

Nothing contained on this page constitutes an offer to sell, an offer to purchase, or a solicitation of an offer to buy or sell any security, investment product, or financial instrument. Nothing on this page constitutes investment advice, a recommendation regarding any security, or a recommendation to enter into any transaction with the profiled firm or any other party.

Any securities transaction, capital-raising engagement, investment-banking engagement, or other securities-related activity involving Auxo Capital Advisors or Weild & Co. is subject to applicable regulatory requirements, internal review and approval, suitability and other applicable diligence requirements, and the terms of a separate written engagement or transaction agreement, as applicable.

Inclusion of a third-party firm in this directory does not imply affiliation with, sponsorship by, endorsement by, or any other relationship with Auxo Capital Advisors or Weild & Co. unless expressly stated otherwise.